The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Open accessAbstract
BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. METHODS: We randomly assigned, in a 1:1:1 ratio, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kilogram of body weight plus ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses, followed by nivolumab at a dose of 3 mg per kilogram every 2 weeks; nivolumab at a dose of 3 mg per kilogram every 2 weeks plus placebo; or ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses plus placebo, until progression, the occurrence of unacceptable toxic effects, or withdrawal of consent. Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage. The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group versus the ipilimumab group. RESULTS: At a minimum follow-up of 36 months, the median overall survival had not been reached in the nivolumab-plus-ipilimumab group and was 37.6 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.55 [P<0.001]; hazard ratio for death with nivolumab vs. ipilimumab, 0.65 [P<0.001]). The overall survival rate at 3 years was 58% in the nivolumab-plus-ipilimumab group and 52% in the nivolumab group, as compared with 34% in the ipilimumab group. The safety profile was unchanged from the initial report. Treatment-related adverse events of grade 3 or 4 occurred in 59% of the patients in the nivolumab-plus-ipilimumab group, in 21% of those in the nivolumab group, and in 28% of those in the ipilimumab group. CONCLUSIONS: Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with nivolumab alone than with ipilimumab alone. (Funded by Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with anti-PD-1 and anti-PD-1/CTLA-4 combination therapy emerging as most effective [3, 4].”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“3-year overall survival rates were 58%, 52%, and 34% in combination therapy, anti-PD-1, and anti-CTLA-4 groups, respectively [4].”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [4]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These chemokines have been identified as the dominant mediators for the recruitment of CXCR3+ and CCR5+ tumor-specific T lymphocytes into the tumors and their intratumoral expression correlated with favorable clinical outcomes in patients with melanoma30–32.”
From Epigenetic state determines the in vivo efficacy of STING agonist therapy (2023) · cites this paper as [30]
Experimental — accuracy not yet measuredIn the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [36]
In the citing paper
“By contrast, ICB has shown promise in the adjuvant setting in patients with melanoma or NSCLC57–59”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 9×
“Asthenia 30 (10) 1 (<1) 25 (8) 1 (<1) 17 (5) 2 (1)”
InfluentialSelf-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · cited 6×
“Asthenia 30 (10) 1 (<1) 25 (8) 1 (<1) 17 (5) 2 (1)”
InfluentialSelf-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 9×
“Increased amylase level 26 (8) 9 (3) 20 (6) 6 (2) 15 (5) 4 (1)”
InfluentialSelf-citationTime‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & PEPE, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,870
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781 · cited 8×
“Asthenia 30 (10) 1 (<1) 25 (8) 1 (<1) 17 (5) 2 (1)”
InfluentialSelf-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Robert C, 2017, J Clin Oncol, 15, 35
- Long GV, Ann Oncol
Cited by
Sorted by citations
Items 701–800 of 1,021
Thomas, M. F., Slowikowski, K., Manakongtreecheep, K., Sen, P., Samanta, N., Tantivit, J., Nasrallah, M., Zubiri, L., Smith, N. P., Tirard, A. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02895-x · Cited by 94
“Because combination therapy increases the risk of irColitis 5–10 fold compared to monotherapy 1 , we investigated transcriptional differences in CD8 T cells from patients with irColitis on PD-1/CTLA-4 blockade versus anti-PD-1 (Fig.”
Modeling Cancer with Flies and Fish
Cagan, R. L., Zon, L. I., & White, R. M. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.013 · Cited by 91
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications
Santoni, M., Massari, F., Nunno, V. D., Conti, A., Cimadamore, A., Scarpelli, M., Montironi, R., Liang Cheng, C., Battelli, N., & Antonio Lopez-beltran, B. (2018) · Drugs in Context · doi:10.7573/dic.212528 · Cited by 86
Current status and perspectives in immunotherapy for metastatic melanoma
Marconcini, R., (IMI), F. T. I. M. I., Spagnolo, F., Stucci, L. S., Ribero, S., Marra, E., Rosa, F. D., Picasso, V., Guardo, L. D., Cimminiello, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23746 · Cited by 84
“Phase 3 trials showed the superiority of such approach when compared to single agent immune checkpoint inhibitors [18].”
Chardin, D., Paquet, M., Schiappa, R., Darcourt, J., Bailleux, C., Poudenx, M., Sciazza, A., Ilié, M., Benzaquen, J., Martin, N., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000645 · Cited by 83
Palmer, A. C., Izar, B., Hwangbo, H., & Sorger, P. K. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2275 · Cited by 85
“Single-agent ICIs have been remarkable in achieving long-lasting “treatment-free survival” for subsets of patients (31, 48).”
Kluger, H. M., Barrett, J. C., Gainor, J. F., Hamid, O., Hurwitz, M. E., LaVallee, T. M., Moss, R. A., Zappasodi, R., Sullivan, R. J., Tawbi, H. A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005921 · Cited by 91
Diab, A. K., Gogas, H. J., Sandhu, S. K., Long, G. V., Ascierto, P. A., Larkin, J., Sznol, M., Franke, F. A., Ciuleanu, T., Pereira, C., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00172 · Cited by 85
“Immunotherapy combinations have revolutionized treatment and extended survival for patients with previously untreated, unresectable, or metastatic melanoma.(1-4) Although up to 60% of patients with advanced melanoma respond to immune checkpoint inhibitor regimens in the first-line setting, nearly 25% of these responde…”
BackgroundMethodInfluentialSelf-citationAnti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma
Suo, A., Chan, Y., Beaulieu, C., Kong, S., Cheung, W. Y., Monzon, J. G., Smylie, M., Walker, J., Morris, D., & Cheng, T. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0674 · Cited by 83
“It is noteworthy that rates of pneumonitis in the current study are high in comparison with previous clinical trial reports [1, 2, 23], although comparable to other institutional reported outcomes [31].”
ResultSelf-citationAnagnostou, V., Bruhm, D. C., Niknafs, N., White, J. R., Shao, X. M., Sidhom, J.-W., Stein, J. E., Tsai, H., Wang, H., Belcaid, Z., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100139 · Cited by 87
Bander, E. D., Yuan, M., Carnevale, J. A., Reiner, A. S., Panageas, K. S., Postow, M. A., Tabar, V. S., & Moss, N. S. (2021) · Cancer · doi:10.1002/cncr.33459 · Cited by 86
“PreBM immunotherapy No 226 (53) Yes 199 (47) PreBM BRAFtargeted therapy No 366 (86) Yes 59 (14) PostBM immunotherapy No 97 Yes 326 (77) Unknown 2 (0) PostBM BRAFtargeted therapy No 317 (75) Yes 108 (25) Surgery None 260 (61) Shunt 7 (2) Craniotomy 147 (35) Both 9 (2) Radiation None 92 (22) SRS 182 (43) WBRT 103 (24) B…”
BackgroundSelf-citationLuo, J., Martucci, V. L., Quandt, Z., Groha, S., Murray, M. H., Lovly, C. M., Rizvi, H. A., Egger, J. V., Plodkowski, A. J., Abu-Akeel, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0921 · Cited by 85
Molecular patterns of resistance to immune checkpoint blockade in melanoma
Lauss, M., Phung, B., Borch, T. H., Harbst, K., Kaminska, K. K., Ebbesson, A., Hedenfalk, I. A., Yuan, J., Nielsen, K., Ingvar, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47425-y · Cited by 90
Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease
Kamath, S. D., & Kumthekar, P. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00414 · Cited by 84
“As a result, the 10 mg/kg dose is uncommon in more recent clinical trials, especially when dual immunotherapy is used, where the 1–3 mg/kg doses are often used (18, 19).”
BackgroundKlemen, N. D., Wang, M., Feingold, P. L., Cooper, K., Pavri, S. N., Han, D., Detterbeck, F. C., Boffa, D. J., Khan, S. A., Olino, K. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0672-3 · Cited by 83
“These data are similar to that reported in the CheckMate 067 trial, but in our series 87 patients (20%) had brain metastases and 35 (8%) had ocular melanomas, both of which were excluded from the Checkmate 067 study [19].”
ResultFirst line Immunotherapy for Non-Small Cell Lung Cancer
Nasser, N. J., Gorenberg, M., & Agbarya, A. (2020) · Pharmaceuticals · doi:10.3390/ph13110373 · Cited by 83
“Ipilimumab was provided at a dose of 1 mg per kilogram every 6 weeks [111], which is much lower than the dose used for melanoma [112].”
BackgroundBempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
Diab, A. K., Tykodi, S. S., Daniels, G. A., Maio, M., Curti, B. D., Lewis, K. D., Jang, S., Kalinka‐Warzocha, E., Puzanov, I. J., Spira, A. I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00675 · Cited by 83
“This compares favorably with the 2-year OS rate for NIVO at 2 years in CheckMate 067 (59% [95% CI, not reported]).(28)”
ResultSelf-citationMucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy
Ma, Y., Xia, R., Ma, X., Judson‐Torres, R. L., & Zeng, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.702287 · Cited by 88
Turiello, R., Capone, M., Morretta, E., Monti, M. C., Madonna, G., Azzaro, R., Gaudio, P. D., Simeone, E., Sorrentino, A., Ascierto, P. A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004043 · Cited by 82
Self-citationImmune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?
Lao, Y., Shen, D., Zhang, W., He, R., & Jiang, M. (2022) · Cancers · doi:10.3390/cancers14153575 · Cited by 87
“In both the single-drug nivolumab group and the single-drug ipilimumab group, the OS and rPFS were much lower [14].”
BackgroundInfluentialEuropean consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024
Garbe, C., Amaral, T. M. S., Peris, K., Hauschild, A., Arenberger, P., Basset‐Séguin, N., Bastholt, L., Bataille, V. A., Brochez, L., del Mármol, V., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115152 · Cited by 88
Self-citationFujimura, T., Kambayashi, Y., Tanita, K., Sato, Y., Hidaka, T., Otsuka, A., Tanaka, H., Furudate, S., Hashimoto, A., & Aiba, S. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14273 · Cited by 82
Kerns, S. J., Belgur, C., Petropolis, D., Kanellias, M., Barrile, R., Sam, J., Weinzierl, T., Fauti, T., Freimoser-Grundschober, A., Eckmann, J., et al. (2021) · eLife · doi:10.7554/elife.67106 · Cited by 82
“The top, epithelial channel is separated with a 161 flexible, porous membrane (4) from a bottom, vascular channel seeded with primary lung microvascular 162 cells (5,6).”
Mitchell, E. L., Lau, P. K. H., Khoo, C. C. H., Liew, D. F. L., Leung, J., Liu, B., Rischin, A., Frauman, A. G., Kee, D., Smith, K. M., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.027 · Cited by 81
Self-citationPembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
Tucker, M. D., Zhu, J., Marin, D., Gupta, R. T., Gupta, S. K., Berry, W. R., Ramalingam, S., Zhang, T., Harrison, M. R., Wu, Y. S., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2375 · Cited by 82
“Skin and subcutaneous tissue disorders: maculopapular rash 1 (1)”
BackgroundCariani, E., & Missale, G. (2019) · Liver International · doi:10.1111/liv.14192 · Cited by 83
Tremble, L. F., McCabe, M., Walker, S. P., McCarthy, S., Tynan, R., Beecher, S. M., Werner, R., Clover, A. J. P., Power, D. G., Forde, P. F., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01037-7 · Cited by 79
From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review
Kuryk, Ł., Bertinato, L., Staniszewska, M., Pancer, K. W., Wieczorek, M., Salmaso, S., Caliceti, P., & Garofalo, M. (2020) · Cancers · doi:10.3390/cancers12103057 · Cited by 85
Fidelle, M., Yonekura, S., Picard, M., Cogdill, A. P., Hollebecque, A., Roberti, M. P., & Zitvogel, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600886 · Cited by 87
Rasmussen, T. A., Rajdev, L. N., Rhodes, A., Dantanarayana, A., Tennakoon, S., Chea, S., Spelman, T. D., Lensing, S., Rutishauser, R. L., Bakkour, S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1530 · Cited by 87
Brown, L. J., Weppler, A. M., Bhave, P., Allayous, C., Patrinely, J. R., Ott, P. A., Sandhu, S. K., Haydon, A. M., Lebbé, C., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002121 · Cited by 83
Self-citationHarrington, K. J., Ferris, R. L., Gillison, M. L., Tahara, M., Argiris, A., Fayette, J., Schenker, M., Bratland, Å., Walker, J. W. T., Grell, P., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.0147 · Cited by 81
Tarhini, A. A., & Kudchadkar, R. R. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.005 · Cited by 84
Hamid, O., Molinero, L. L., Bolen, C. R., Sosman, J. A., Muñoz‐Couselo, E., Kluger, H. M., McDermott, D. F., Powderly, J. D., Sarkar, I., Ballinger, M. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3488 · Cited by 82
“Combination of PD-L1/PD-1 inhibitors with CTLA-4–targeted agents has yielded higher response rates (6).”
BackgroundSelf-citationRegan, M. M., Werner, L. L., Rao, S. A., Gupte-Singh, K., Hodi, F. S., Kirkwood, J. M., Kluger, H. M., Larkin, J., Postow, M. A., Ritchings, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00345 · Cited by 80
“The introduction of single-agent and combination ICI therapy for patients with advanced melanoma has contributed to an improvement in OS from a median of 6 to 9 months(3) to more than 4 years.(4,6,10) Combination ICI therapy with nivolumab plus ipilimumab significantly prolonged PFS and OS and increased the objective…”
BackgroundMethodSelf-citationCTLA-4 (CD152): A versatile receptor for immune-based therapy
Lingel, H., & Brunner-Weinzierl, M. C. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101298 · Cited by 82
Da, L., Teng, Y., Wang, N., Zaguirre, K., Liu, Y., Qi, Y., & Song, F. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01671 · Cited by 84
“, 2017 2015/ 2017 Phase III RCT; Check Mate 067 Melanoma 59 (2590) 316 (202/144) NIVO(3 mg/kg q2w) 3 4.”
MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
Forschner, A., Hilke, F.-J., Bonzheim, I., Gschwind, A., Demidov, G. M., Amaral, T. M. S., Ossowski, S., Rieß, O., Schroeder, C., Martus, P., et al. (2020) · Cancers · doi:10.3390/cancers12030540 · Cited by 81
Antoniotti, C., Borelli, B., Rossini, D., Pietrantonio, F., Morano, F., Salvatore, L., Lonardi, S., Marmorino, F., Tamberi, S., Corallo, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07169-6 · Cited by 82
Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma
Dummer, R., Ascierto, P. A., Nathan, P., Robert, C., & Schadendorf, D. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4401 · Cited by 81
Self-citationPredictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
Xu, Y., Fu, Y., Zhu, B., Wang, J., & Zhang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02023 · Cited by 83
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients
Zaremba, A., Eggermont, A. M. M., Robert, C., Dummer, R., Ugurel, S., Livingstone, E., Ascierto, P. A., Long, G. V., Schadendorf, D., & Zimmer, L. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.07.002 · Cited by 81
Self-citationTsukamoto, H., Komohara, Y., Tomita, Y., Miura, Y., Motoshima, T., Imamura, K., Kimura, T., Ikeda, T., Fujiwara, Y., Yano, H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205378119 · Cited by 86
“Consequently, patients with serious irAEs are permanently required to discontinue the ICB treatment regardless of its substantial antitumor effects (3, 5, 8).”
BackgroundInfluentialNewly developed 3D in vitro models to study tumor–immune interaction
Mu, P., Zhou, S., Lv, T., Xia, F., Shen, L., Wan, J., Wang, Y., Zhang, H., Cai, S., Peng, J., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02653-w · Cited by 87
Wang, B., Yin, H., Zhang, Y., Zhao, Q., Wang, H., Wei, J., Meng, L., Xin, Y., & Jiang, X. M. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01073-9 · Cited by 85
Pinato, D. J., Cortellini, A., Sukumaran, A., Cole, T., Pai, M., Habib, N., Spalding, D., Sodergren, M. H., Martinez, M., Dhillon, T., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08033-x · Cited by 79
Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?
De Bruyn, P., Van Gestel, D., Ost, P., Kruse, V., Brochez, L., Van Vlierberghe, H., Devresse, A., del Marmol, V., Le Moine, A., & Aspeslagh, S. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000505 · Cited by 79
Immunotherapy of Primary Brain Tumors: Facts and Hopes
Buerki, R. A., Chheda, Z. S., & Okada, H. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2769 · Cited by 82
Manukian, G., Bar‐Ad, V., Lü, B., Argiris, A. E., & Johnson, J. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00122 · Cited by 83
B2M overexpression correlates with malignancy and immune signatures in human gliomas
Zhang, H., Cui, B., Zhou, Y., Wang, X., Wu, W., Wang, Z., Dai, Z., Cheng, Q., & Yang, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-84465-6 · Cited by 79
Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
Kalfeist, L., Galland, L., Ledys, F., Ghiringhelli, F., Limagne, E., & Ladoire, S. (2022) · Cells · doi:10.3390/cells11050770 · Cited by 78
Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy
Fang, C., Xiao, G., Wang, T., Li, S., Peng, B., Xu, B., & Zhang, K. (2023) · Research · doi:10.34133/research.0108 · Cited by 79
Microbiota-driven antitumour immunity mediated by dendritic cell migration
Lin, Y.-T., Fukuoka, S., Koyama, S., Motooka, D., Tourlousse, D. M., Shigeno, Y., Matsumoto, Y., Yamano, H., Murotomi, K., Tamaki, H., et al. (2025) · Nature · doi:10.1038/s41586-025-09249-8 · Cited by 84
Control of NK Cell Activation by Immune Checkpoint Molecules
Beldi‐Ferchiou, A., & Caillat‐Zucman, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102129 · Cited by 81
Waliany, S., Lee, D. C., Witteles, R. M., Neal, J. W., Nguyen, P. K. P., Davis, M. M., Salem, J., Wu, S. M., Moslehi, J. J., & Zhu, H. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023451 · Cited by 77
Massari, F., Mollica, V., Rizzo, A., Cosmai, L., Rizzo, M., & Porta, C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1811226 · Cited by 81
Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience
Fortes, B. H., Liou, H., & Dalvin, L. A. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316970 · Cited by 79
Combination immunotherapy strategies for glioblastoma
Chan, H. Y., Choi, J. H., Jackson, C., & Lim, M. K. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03481-0 · Cited by 79
Zhou, B., Gao, Y., Zhang, P., & Chu, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693609 · Cited by 81
Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials
Panagiotou, Ε., Gomatou, G., Trontzas, I. P., Syrigos, N. K., & Kotteas, E. A. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02688-5 · Cited by 76
Ning, B., Liu, Y., Wang, M., Li, Y., Xu, T., & Wei, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.748674 · Cited by 83
Liu, Z., Zhu, Y., Xie, H., & Zou, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1077468 · Cited by 84
“Meanwhile, compared to monotherapy, combined immunotherapy has higher incidence in most of irAEs and more than 60% of patients treated with combined therapy have been reported to occur severe irAEs (Wolchok et al., 2017; Esfahani et al., 2019).”
BackgroundOncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective
Muthukutty, P., & Yoo, S. Y. (2023) · Viruses · doi:10.3390/v15081645 · Cited by 84
“The development of monoclonal antibodies that can target these checkpoint inhibitors has been demonstrated in studies of solid tumors [100,101].”
BackgroundThe Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities
Garlisi, B., Lauks, S., Aitken, C., Ogilvie, L. M., Lockington, C., Petrik, D., Eichhorn, J. S., & Petrik, J. (2024) · Current Oncology · doi:10.3390/curroncol31070283 · Cited by 91
Shen, H., Ojo, O. A., Ding, H., Mullen, L. J., Xing, C., Hossain, M. I., Yassin, A., Shi, V. Y., Lewis, Z., Podgórska, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53593-8 · Cited by 90
“ICBs have emerged as a major pillar of cancer care 54 – 59 .”
Dobry, A. S., Zogg, C. K., Hodi, F. S., Smith, T. R., Ott, P. A., & Iorgulescu, J. B. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2241-x · Cited by 76
Self-citationJiang, C., Zhang, L., Xu, X., Qi, M., Zhang, J., He, S., Tian, Q., & Song, S. (2021) · Advanced Science · doi:10.1002/advs.202102500 · Cited by 77
PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival
Micevic, G., Thakral, D., McGeary, M. K., & Bosenberg, M. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12745 · Cited by 79
“Immune checkpoint blockade therapies have demon‐ strated promising efficacy, inducing high rates of antimelanoma im‐ mune response (Wolchok et al., 2017), and even robust complete responses in some cases (Schadendorf et al., 2015; Wolchok et al., 2013).”
BackgroundLanier, C. M., Hughes, R. T., Ahmed, T., LeCompte, M. C., Masters, A. H., Petty, W. J., Ruiz, J., Triozzi, P. L., Su, J., O’Neill, S., et al. (2019) · Neuro-Oncology Practice · doi:10.1093/nop/npz004 · Cited by 77
Fässler, M., Diem, S., Mangana, J., Ali, O. H., Berner, F., Bomze, D., Ring, S. S., Niederer, R., Gil‐Cruz, C., Perez‐Shibayama, C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0523-2 · Cited by 77
“4370) or MelanA/MART1 and its antigen expression (r [9] = − .”
BackgroundSelf-citationKanaya, N., Kuroda, S., Kakiuchi, Y., Kumon, K., Tsumura, T., Hashimoto, M., Morihiro, T., Kubota, T., Aoyama, K., Kikuchi, S., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.003 · Cited by 82
Targeting AKT/PKB to improve treatment outcomes for solid tumors
Iida, M., Harari, P. M., Wheeler, D. L., & Toulany, M. (2020) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2020.111690 · Cited by 77
Park, R., da Silva, L. L., Cristancho, C., Riaño, I., & Saeed, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00258 · Cited by 78
“(18) Melanoma PD-1 + CTLA-4 CTLA-4, PD-1 III N1I3 5 4 313”
The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer
Tang, Y., Zhang, P., Wang, Y., Wang, J., Su, M., Wang, Y., Zhou, L., Zhou, J., Xiong, W., Zeng, Z., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00604 · Cited by 81
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors
Alaiwi, S. A., Nassar, A. H., Xie, W., Bakouny, Z., Berchuck, J. E., Braun, D. A., Baca, S. C., Nuzzo, P. V., Flippot, R., Mouhieddine, T. H., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0866 · Cited by 80
Self-citationEZH2 Inhibition: A Promising Strategy to Prevent Cancer Immune Editing
Kang, N., Eccleston, M., Clermont, P., Latarani, M., Male, D. K., Wang, Y. Z., & Crea, F. (2020) · Epigenomics · doi:10.2217/epi-2020-0186 · Cited by 79
Quagliariello, V., Laurentiis, M. D., Cocco, S., Rea, G., Bonelli, A., Caronna, A., Lombari, M. C., Conforti, G., Berretta, M., Botti, G., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207802 · Cited by 76
Ceci, C., Atzori, M. G., Lacal, P. M., & Graziani, G. (2020) · Cancers · doi:10.3390/cancers12113401 · Cited by 79
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function
Jessel, S., Weiss, S. A., Austin, M., Mahajan, A. K., Etts, K., Zhang, L., Aizenbud, L., Perdigoto, A. L., Hurwitz, M. E., Sznol, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836859 · Cited by 79
“5% for PD-1 inhibitors (2, 12, 14), and up to 13% for combination therapy with ipilimumab plus nivolumab (10, 15, 16).”
BackgroundKreidieh, F., & Tawbi, H. A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231186027 · Cited by 87
Sullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., Fecher, L. A., Gajewski, T. F., Gastman, B., Lawson, D. H., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0362-6 · Cited by 80
“receiving nivolumab or ipilimumab alone, respectively [58].”
BackgroundInfluentialSelf-citationCirculating CD56bright NK cells inversely correlate with survival of melanoma patients
de Jonge, K., Ebering, A., Nassiri, S., Hajjami, H. M.-E., Ouertatani-Sakouhi, H., Baumgaertner, P., & Speiser, D. E. (2019) · Scientific Reports · doi:10.1038/s41598-019-40933-8 · Cited by 82
Broman, K. K., Dossett, L. A., Sun, J. X., Eroglu, Z., & Zager, J. S. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1607289 · Cited by 76
Spontaneously occurring melanoma in animals and their relevance to human melanoma
van der Weyden, L., Brenn, T., Patton, E. E., Wood, G. A., & Adams, D. J. (2020) · The Journal of Pathology · doi:10.1002/path.5505 · Cited by 76
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 76
Systemic Therapy of Metastatic Melanoma: On the Road to Cure
Steininger, J., Gellrich, F. F., Schulz, A., Westphal, D., Beissert, S., & Meier, F. E. (2021) · Cancers · doi:10.3390/cancers13061430 · Cited by 79
The gut microbiome and efficacy of cancer immunotherapy
Roviello, G., Iannone, L. F., Bersanelli, M., Mini, E., & Catalano, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107973 · Cited by 77
Isoyama, S., Mori, S., Sugiyama, D., Kojima, Y., Tada, Y., Shitara, K., Hinohara, K., Dan, S., & Nishikawa, H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002279 · Cited by 76
“25 In this combination therapy, nivolumab followed by ipilimumab appears to be more clinically beneficial compared with the opposite order.”
Targeted Therapy and Immunotherapy in Melanoma
Lazaroff, J. M., & Bolotin, D. (2022) · Dermatologic Clinics · doi:10.1016/j.det.2022.07.007 · Cited by 77
“How Much Time Do I Have?”: Communicating Prognosis in the Era of Exceptional Responders
LeBlanc, T. W., Temel, J. S., & Helft, P. R. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201211 · Cited by 74
The evolutionary legacy of immune checkpoint inhibitors
Kaushik, I., Ramachandran, S., Zabel, C., Gaikwad, S., & Srivastava, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.020 · Cited by 79
Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders
Jannin, A., Penel, N., Ladsous, M., Vantyghem, M., & Cao, C. D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.015 · Cited by 77
Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature
Chan, K. K., MAGRO, C. M. J., Shoushtari, A. N., Rudin, C. M., Rotemberg, V. M., Rossi, A., Lezcano, C. M., Carrino, J. A., Fernández, D., Postow, M. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0508 · Cited by 76
“For advanced cutaneous melanoma, the rate of complete response to nivolumab in clinical trials is 16% [41].”
BackgroundSelf-citationA gene expression-based study on immune cell subtypes and glioma prognosis
Zhong, Q.-Y., Fan, E., Feng, G., Chen, Q., Gou, X., Yue, G., & Zhang, G.-H. (2019) · BMC Cancer · doi:10.1186/s12885-019-6324-7 · Cited by 75
Cryoablation and immunotherapy of cancer
Yakkala, C., Denys, A. L., Kandalaft, L. E., & Durán, R. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.01.006 · Cited by 75
Shimozaki, K., Sukawa, Y., Beppu, N., Kurihara, I., Suzuki, S., Mizuno, R., Funakoshi, T., Ikemura, S., Tsugaru, K., Togasaki, K., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s247554 · Cited by 77
Shenderov, E., Boudadi, K., Fu, W., Wang, H., Sullivan, R., Jordan, A., Dowling, D., Harb, R., Schonhoft, J. D., Jendrisak, A., et al. (2021) · The Prostate · doi:10.1002/pros.24110 · Cited by 75
Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes
Osarogiagbon, R. U., Sineshaw, H. M., Unger, J. M., Acuña-Villaorduña, A., & Goel, S. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_323523 · Cited by 80
Physical and Biological Characteristics of Particle Therapy for Oncologists
Byun, H. K., Han, M. C., Yang, K., Kim, J. S., Yoo, G. S., Koom, W. S., & Kim, Y. B. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2021.066 · Cited by 76
Giacomo, A. M. D., Chiarion‐Sileni, V., Vecchio, M. D., Ferrucci, P. F., Guida, M., Quaglino, P., Guidoboni, M., Marchetti, P., Cutaia, O., Amato, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1046 · Cited by 75
Self-citation
Metadata
- Authors
- Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., Smylie, M., Dummer, R., Hill, A., Hogg, D., Haanen, J., Carlino, M. S., Bechter, O., Maio, M., Marquez-Rodas, I., Guidoboni, M., McArthur, G., Lebbé, C., Ascierto, P. A., Long, G. V., Cebon, J., Sosman, J., Postow, M. A., Callahan, M. K., Walker, D., Rollin, L., Bhore, R., Hodi, F. S., & Larkin, J.
- Affiliations
- University of Siena (IT)
- From the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W., M.A.P., M.K.C.); Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua (V.C.-S.), European Institute of Oncology, Milan (P.F.F.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.),...
- ORCID
- Wolchok, Jedd D.
- Gonzalez, Rene
- Rutkowski, Piotr
- Grob, Jean-Jacques
- Cowey, C. Lance
- Wagstaff, John
- Schadendorf, Dirk
- Ferrucci, Pier F.
- Smylie, Michael
- Dummer, Reinhard
- Hogg, David
- Haanen, John
- Carlino, Matteo S.
- Bechter, Oliver
- Maio, Michele
- Guidoboni, Massimo
- McArthur, Grant
- Ascierto, Paolo A.
- Long, Georgina V.
- Cebon, Jonathan
- Sosman, Jeffrey
- Postow, Michael A.
- Callahan, Margaret K.
- Bhore, Rafia
- Hodi, F. Stephen
- Larkin, James
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-10-05
- Volume
- 377
- Issue
- 14
- Pages
- 1345-1356
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5706778
- OpenAlex
- W2753432434
- Semantic Scholar
- 23dbeed54cde655fb6a12697b02c9ff303515da7
- Cited by
- 5,357
- References
- 18
- Citations by year
- 2026: 159 · 2025: 282 · 2024: 569 · 2023: 705 · 2022: 746 · 2021: 947 · 2020: 900 · 2019: 578 · 2018: 428 · 2017: 37
- FWCI
- 234.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Use Siena air (University of Siena) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Lirias (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- advanced melanoma, nivolumab, ipilimumab, combination immunotherapy, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, overall survival, progression-free survival, treatment-related adverse events, immune-related adverse events, PD-L1 expression, BRAF mutation, long-term follow-up
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Humans, Melanoma, Middle Aged, Neoplasm Staging, Skin Neoplasms, Survival Rate, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
